Experimental cell therapy trial offers hope for Tough-to-Treat lupus
NCT ID NCT06265220
Summary
This early-stage trial is testing a new cell therapy called AB-101 for adults with severe lupus nephritis or other hard-to-treat forms of lupus who haven't responded to standard treatments. AB-101 is made from donated natural killer (NK) cells, a type of immune cell, and is given alone or alongside a B-cell depleting drug. The main goals are to check the safety of the treatment and see if it helps control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Artiva Investigational Site Aventura
Aventura, Florida, 33180, United States
-
Artiva Investigational Site Birmingham
Birmingham, Alabama, 35249, United States
-
Artiva Investigational Site Charlotte
Charlotte, North Carolina, 28625, United States
-
Artiva Investigational Site Iowa
Iowa City, Iowa, 52242, United States
-
Artiva Investigational Site Mesquite
Mesquite, Texas, 75150, United States
-
Artiva Investigational Site Plantation
Plantation, Florida, 33324, United States
-
Artiva Investigational Site San Diego
San Diego, California, 92121, United States
-
Artiva Investigational Site Tucson
Tucson, Arizona, 85724, United States
-
Artiva Investigational Site Woodlands
The Woodlands, Texas, 77382, United States
Conditions
Explore the condition pages connected to this study.